Synthetic Biologics Inc - ESG Rating & Company Profile powered by AI
The assessment of Synthetic Biologics Inc was assembled by All Street Sevva using leading Cognitive Robots. The Sustainability rating for Synthetic Biologics Inc indicates the company's transparency towards the UN Sustainable Development Goals. Full ESG analysis of Synthetic Biologics Inc are accessed by signing in.
Synthetic Biologics Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 6.9; made up of an environmental score of 6.0, social score of 6.7 and governance score of 6.9.
6.9
Medium ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Novartis AG | 9.2 | High |
| 2 | Daiichi Sankyo Co Ltd | 8.9 | High |
| 355 | Xbrane Biopharma AB | 7.0 | High |
| 355 | Xenetic Biosciences Inc | 7.0 | High |
| 387 | Synthetic Biologics Inc | 6.9 | High |
| 387 | Advanced Medical Solutions Group PLC | 6.9 | High |
| 387 | Acrux Ltd | 6.9 | High |
| ... | ... | ... | |
| 2749 | Xynomic Pharmaceuticals Holdings Inc | 0.0 | Low |
| 2749 | Zyden Gentec Ltd | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Synthetic Biologics Inc have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Synthetic Biologics Inc disclose current and historical energy intensity?
Sign up for free to unlockDoes Synthetic Biologics Inc report the average age of the workforce?
Sign up for free to unlockDoes Synthetic Biologics Inc reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Synthetic Biologics Inc disclose its ethnicity pay gap?
Sign up for free to unlockDoes Synthetic Biologics Inc disclose cybersecurity risks?
Sign up for free to unlockDoes Synthetic Biologics Inc offer flexible work?
Sign up for free to unlockDoes Synthetic Biologics Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Synthetic Biologics Inc disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Synthetic Biologics Inc conduct supply chain audits?
Sign up for free to unlockDoes Synthetic Biologics Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Synthetic Biologics Inc conduct 360 degree staff reviews?
Sign up for free to unlockDoes Synthetic Biologics Inc disclose the individual responsible for D&I?
Sign up for free to unlockDoes Synthetic Biologics Inc disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Synthetic Biologics Inc disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Synthetic Biologics Inc disclose water use targets?
Sign up for free to unlockDoes Synthetic Biologics Inc have careers partnerships with academic institutions?
Sign up for free to unlockDid Synthetic Biologics Inc have a product recall in the last two years?
Sign up for free to unlockDoes Synthetic Biologics Inc disclose incidents of discrimination?
Sign up for free to unlockDoes Synthetic Biologics Inc allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Synthetic Biologics Inc issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Synthetic Biologics Inc disclose parental leave metrics?
Sign up for free to unlockDoes Synthetic Biologics Inc disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Synthetic Biologics Inc disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Synthetic Biologics Inc disclose the pay ratio of women to men?
Sign up for free to unlockDoes Synthetic Biologics Inc support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Synthetic Biologics Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Synthetic Biologics Inc reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Synthetic Biologics Inc involved in embryonic stem cell research?
Sign up for free to unlockDoes Synthetic Biologics Inc disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Synthetic Biologics Inc disclose its waste policy?
Sign up for free to unlockDoes Synthetic Biologics Inc report according to TCFD requirements?
Sign up for free to unlockDoes Synthetic Biologics Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Synthetic Biologics Inc disclose energy use targets?
Sign up for free to unlockDoes Synthetic Biologics Inc disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Synthetic Biologics Inc have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Synthetic Biologics Inc
These potential risks are based on the size, segment and geographies of the company.
Synthetic Biologics, Inc., a clinical-stage company, develops therapeutics to treat diseases in areas of high unmet need. The company's lead product candidates include SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. It also develops VCN-01 for the treatment of patients with pancreatic cancer, head and neck squamous cell carcinoma, colorectal cancer, and retinoblastoma. In addition, the company develops clinical stage products, such as SYN-006 to prevent aGVHD and infection by carbapenem resistant enterococci; SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics; SYN-005 for the prevention and treatment of pertussis; and VCN-11 to treat cancer. It has collaborations with Intrexon Corporation, The University of Texas at Austin, and Cedars-Sinai Medical Center; and a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. Synthetic Biologics, Inc. is headquartered in Rockville, Maryland.